Mmm hmm. Via: Slashdot: “During a decade as head of global cancer research at Amgen, C. Glenn Begley identified 53 ‘landmark’ publications — papers in top journals, from reputable labs — for his team to reproduce. Begley sought to double-check the findings before trying to build on them for drug development. Result: 47 of the … Continue reading Majority of Landmark Cancer Studies Cannot Be Replicated